Hulvershorn Leslie, Parkhurst Samantha, Jones Shannon, Dauss Kristin, Adams Caitlin
1 Department of Psychiatry, Indiana University School of Medicine , Indianapolis, Indiana.
2 Evansville Psychiatric Children's Center , Indiana Family and Social Services Agency, Evansville, Indiana.
J Child Adolesc Psychopharmacol. 2017 Dec;27(10):897-907. doi: 10.1089/cap.2017.0040. Epub 2017 Sep 7.
To assess the impact of antipsychotic tapering and discontinuation on measures of metabolic functioning and psychiatric symptom severity in severely impaired youth hospitalized in a psychiatric state hospital.
The study examined psychiatric and metabolic measures in 67 hospitalized children and adolescents (mean age 11.9; 56 with discontinued use of antipsychotics, 10 with continued use of antipsychotics, and 1 started on an antipsychotic) from admission to discharge.
Upon admission, 56 youth were tapered off of antipsychotic medications, started on other forms of pharmacotherapy (92.9% were started on medications used to treat attention-deficit/hyperactivity disorder), and received evidence-based behavioral programming and were ultimately discharged from the hospital. The mean duration of treatment was 228 days for the discontinuation group and 204 days for the continuation group. Significant decreases in body mass index [BMI; t(53) = 7.12, p = 0.0001] and BMI percentile [t(53) = 6.73, p = 0.0001] were found from admission to discharge in the antipsychotic discontinuation group. Changes in BMI, BMI percentile, or systolic blood pressure were not found in the group (n = 10) who were maintained on antipsychotics. Both groups experienced a significant increase in their Global Assessment of Functioning score [t(52) = 19.98, p = 0.0001 for discontinued; t(8) = 5.092, p = 0.001 for maintained]. Psychiatric symptom severity scores significantly improved in many subscales relevant to disruptive behaviors and mood disorders for those who were removed from the medications. For those maintained on the antipsychotics, there were fewer changes in psychiatric symptom scores.
Discontinuation of atypical antipsychotic medications in conjunction with tailoring treatment to presenting diagnoses resulted in metabolic and psychiatric symptom improvement among severely impaired state hospital inpatient youth. These results serve as a feasibility demonstration that discontinuation of antipsychotics does not provoke psychiatric destabilization, particularly among disruptive behavior disordered youth.
评估在精神病州立医院住院的严重受损青少年中,抗精神病药物逐渐减量和停药对代谢功能指标及精神症状严重程度的影响。
该研究对67名住院儿童和青少年(平均年龄11.9岁;56名停用抗精神病药物,10名继续使用抗精神病药物,1名开始使用抗精神病药物)从入院到出院期间的精神和代谢指标进行了检查。
入院时,56名青少年逐渐停用抗精神病药物,开始使用其他形式的药物治疗(92.9%开始使用用于治疗注意力缺陷/多动障碍的药物),并接受循证行为规划,最终出院。停药组的平均治疗时长为228天,继续用药组为204天。抗精神病药物停药组从入院到出院,体重指数[BMI;t(53)=7.12,p=0.0001]和BMI百分位数[t(53)=6.73,p=0.0001]显著下降。继续使用抗精神病药物的组(n=10)未发现BMI、BMI百分位数或收缩压有变化。两组的总体功能评估得分均显著提高[停药组t(52)=19.98,p=0.0001;继续用药组t(8)=5.092,p=0.001]。对于停用药物的青少年,与破坏性行为和情绪障碍相关的许多子量表中的精神症状严重程度得分显著改善。对于继续使用抗精神病药物的青少年,精神症状得分变化较少。
停用非典型抗精神病药物并根据当前诊断调整治疗,可使严重受损的州立医院住院青少年的代谢和精神症状得到改善。这些结果证明了停用抗精神病药物不会引发精神不稳定,特别是在患有破坏性行为障碍的青少年中,具有可行性。